

PRECEPTORSHIP PROGRAMME

Immuno-Oncology

From the essentials of tumour
immunology to clinical application

SINGAPORE

26-27 NOVEMBER 2018

Co-Chairs John B.A.G. Haanen, NL
 Ross A. Soo, SG

ESMO PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY

From the essentials of tumour immunology to clinical application

Singapore
26-27 November 2018

CO-CHAIRS:

John B.A.G. Haanen, Netherlands
Ross A. Soo, Singapore

SPEAKERS:

Yung-Jue Bang, South Korea	Soon Thye Lim, Singapore
Anthony T. C. Chan, Hong Kong	Kenneth J. O'Byrne, Australia
Cheng Ean Chee, Singapore	Solange Peters, Switzerland
Teh-Ying Chou, Taiwan	David S. P. Tan, Singapore
Ravindran Kanesvaran, Singapore	Michele Teng, Australia
Sung-Bae Kim, South Korea	Han Chong Toh, Singapore
Claus-Henning Köhne, Germany	Baiyan Wang, China
Soo Chin Lee, Singapore	

LEARNING OBJECTIVES

- To understand the basics of tumour immunology
- To learn about the essentials of immunotherapies and their present indication in cancer treatment
- To learn about the status of development and clinical experience of immunotherapy in different tumour types

ACCREDITATION

The programme of this event has been accredited with **11 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Monday, 26 November 2018

09:00-09:10 10'	Welcome	John B.A.G. Haanen, NL Ross A. Soo, SG
09:10-10:40 90'	SESSION 1 - Introduction	
20'	History of cancer immunology and immunotherapy	John B.A.G. Haanen, NL
30'	Principles of tumour immunology - Cellular and humoral response to TAAs - Immunosurveillance	Michele Teng, AU
25'	Immunotherapy	Han Chong Toh, SG
15'	Discussion	Faculty
10:40-11:00	Coffee break	
11:00-12:35 95'	SESSION 2 - Recent advances with ICPI: Results in approved / unapproved indication (Part 1)	
30'	Melanoma advanced and adjuvant	John B.A.G. Haanen, NL
30'	Non-Small-Cell Lung Cancer	Ross A. Soo, SG
20'	Head and neck cancer	Anthony T. C. Chan, HK
15'	Discussion	Faculty
12:35-13:35	Lunch	
13:35-15:25 110'	SESSION 3 - Clinical issues (Part 1)	
20'	Assessment of efficacy	Kenneth J. O'Byrne, AU
20'	Immune related toxicities and management	John B.A.G. Haanen, NL
20'	Biomarkers: PD-L1	Teh-Ying Chou, TW
20'	Biomarkers: Beyond PD-L1	Solange Peters, CH
20'	Cost of immuno-oncology treatment	Solange Peters, CH
10'	Discussion	Faculty
15:25-15:55	Coffee break	
15:55-17:25 90'	SESSION 4 - Recent advances with ICPI: Results in approved / unapproved indication (Part 2)	
20'	Oesophageal and gastric cancer	Yung-Jue Bang, KR
20'	Hepatocellular carcinoma	Cheng Ean Chee, SG
20'	Colorectal cancer	Claus-Henning Köhne, DE
15'	Gynaecological malignancies	David S. P. Tan, SG
15'	Discussion	Faculty

17:25-18:05 40'	SESSION 5 - Audience cases	
40'	Participants clinical case discussion (4x10')	Faculty
19:45	Dinner	

Tuesday, 27 November 2018

08:30-10:05 95'	SESSION 6 - Recent advances with ICPI: Results in approved / unapproved indication (Part 3)	
30'	Advanced urinary cancer (renal and bladder)	Ravindran Kanesvaran, SG
25'	Hodgkin's lymphoma and other haematological malignancies	Soon Thye Lim, SG
25'	Breast cancer	Soo Chin Lee, SG
15'	Discussion	Faculty
10:05-10:30	Coffee break	
10:30-11:00 30'	SESSION 7 - Clinical issues (Part 2)	
20'	Duration of therapy	Ross A. Soo, SG
10'	Discussion	Faculty
11:00-11:40 40'	SESSION 8 - Audience cases	
40'	Participants clinical case discussion (4x10')	Faculty
11:40-12:40 60'	SESSION 9 - Future of immuno-oncology	
25'	CAR T-Cell therapy	Baiyan Wang, CN
25'	Combination therapy	Sung-Bae Kim, KR
10'	Discussion	Faculty
12:40-12:50 10'	Closure and farewell	John B.A.G. Haanen, NL Ross A. Soo, SG
12:50-14:00	Lunch	

Note: Each 10 minute slot for clinical case discussion includes 5' case presentation and 5' Q&A / panel discussion